title: Statewide support of thrombocytopenic patients with ABO matched single donor platelets.
abstract: Use of ABO matched, HLA nonmatched platelet units obtained from single donors by pheresis, using the Haemonetics 30 Cell Separator, has a lowered hepatitis risk, and possibly delays the onset of the refractory state. Pheresis also offers a method of obtaining HLA matched platelets for the already refractory patient. A mean of 4.2 X 10(11) platelets are collected in about 1 1/2 hours. ABO matched, HLA nonmatched platelets produced corrected increments of more than 2500/mm3 per 7 X 10(10) platelets infused in 67 per cent of transfusions to nonselected recipients. The procedure is simple, safe, and requires little time. It is a worthwhile large-scale program for a regional blood center to undertake in order to provide optimal therapy for thrombocytopenic patients.
mesh_terms: D000017:ABO Blood-Group System; D001772:Blood Cell Count; D001782:Blood Donors; D001792:Blood Platelets; D001804:Blood Transfusion, Autologous / Q000379:methods*; D003237:Connecticut; D005260:Female; D006680:HLA Antigens; D006801:Humans; D008297:Male; D012011:Red Cross; D013921:Thrombocytopenia / Q000628:therapy*
chemical_list: D000017:ABO Blood-Group System; D006680:HLA Antigens